China

Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.

Contribution to Group revenue

Revenue contribution - by therapeutic category

China made up 37% of the total Asian pharmaceutical sector with an estimated value of USD80 billion as at 30 December 2016.
Over the same period, the China pharmaceutical sector grew 7,9% in local currency, mostly driven by the 8,4% growth in prescription medication usage in hospitals.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2017: nil)

Number of product recalls:

Nil

(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USDnil

3 – 5 years

USD13 million

Average staff turnover:

25,9%

(2017: 0,0%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	2 480	1 748	42
Commercial Pharmaceuticals	2 415	1 748	38
Anaesthetics	1 779	1 435	24
Thrombosis	616	266	>100
High Potency & Cytotoxics	20	47	(57)
Nutritionals	65	–	100